Genocea Biosciences, Inc., a clinical-stage company advancing T cell vaccines for infectious diseases, has raised $30 million in a Series C financing round. Genocea is currently enrolling a Phase 1/2a study of GEN-003 and expects to report preliminary data in the second half of 2013. The company anticipates beginning clinical trials in late 2013 for GEN-004, a next-generation vaccine to address Pneumococcal infections, which currently drives the largest global vaccine market, by value. GEN-004 is designed to cover all serotypes of Pneumococcus, rather than the select strains addressed by existing vaccines, and to affect nasopharyngeal colonization caused by Pneumococcus via a TH17 mediated mechanism of action which complements the B cell-mediated effect of existing vaccines.
CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, has raised €80 million financing round, bringing total raised capital to about €145 mill. In the next years, CureVac will use the proceeds mainly to advance the development of its two lead RNActive® cancer vaccines against prostate cancer and non-small cell lung cancer (NSCLC), respectively. CureVac technology is based on a major new understanding of the medical potential of mRNA, and that novel mRNA vaccines and RNA-based adjuvants may transform the treatment of many debilitating diseases, including prostate and lung cancer, as well as the prophylaxis of many infectious diseases.
Vaccine Research Center Seminar Series, Winter 2012:
- Jan 24 Jeff Cohen NIAID, NIH – Herpes simplex virus 2 vaccines: Beyond glycoprotein
- Jan 31 Chris Walker Ohio State University – Immune control of persistent hepatitis C virus infection
- Feb 7 Fred Alt Harvard University – High throughput analysis of mechanisms that influence chromosomal rearrangements and translocations in lymphocytes
- Feb 14 Jim Crowe Vanderbilt University – Genetic and structural complexity of human antibody repertoires
- Feb 21 Ed Mocarski Emory University – Caspase-8 and RIP3-dependent death pathways: lessons from Cytomegalovirus
- Feb 28 Pat Earl NIAID, NIH – Small animal models of lethal injection for studying monkeypox virus
- Mar 6 Robin Shattock St. George’s Hosp., Univ. London – Vaginal antibodies as a determinant of HIV susceptibility
- Mar 13 Charles Mackay Monash University – Dietary and microbiome influences on gut health and inflammatory disease
- Apr 10 Rick Blumberg Brigham and Women’s Hospital – The immunological functions of the (not so) neonatal FcR for IgG
- Apr 17 Gepi Pantaleo University of Lausanne – T-cell immunity in HIV infection and vaccine development
For more information, please see http://vrc.nih.gov/cgi-shl/vrc/seminars.cfm
Sinovac Begins the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease
Sinovac Biotech Ltd.begins the phase III clinical trial for its proprietary inactivated EV71 vaccine against hand, foot and mouth disease (HFMD). The Phase II trial, completed in November 2011, confirmed favorable safety and tolerance profiles, and good immunogenicity. According to the results of phase II clinical trial, the formulation of 400U with aluminum adjuvant was selected to be used in phase III clinical trial to evaluate the efficacy of Sinovac’s EV71 vaccine in protecting against HFMD. The Phase III clinical trial is expected to enroll up to 10,000 healthy volunteers with ages 6-35 months, and was designed as a randomization, double blinded, placebo controlled study. The vaccination schedule calls for two shots at 0 and 28 days. Sinovac anticipates the trial to be completed in the first half of 2013.
Military researchers here have developed a cutting-edge cancer vaccine that’s slashing breast cancer recurrence rates and giving some survivors a better shot at a cancer-free future. After more than a decade of research and testing, the cancer vaccine, dubbed E-75, soon will move on to its final phase of testing to earn Food and Drug Administration approval, said Army Col. (Dr.) George E. Peoples, director and principal investigator for the Cancer Vaccine Development Program at San Antonio Military Medical Center.
SEEK, a UK privately-owned drug-discovery group, reports preliminary successful trials of a new vaccine that provides lifetime protection against all influenza strains after single vaccination. The Seek’s press release says that the Universal Flu vaccine could be available for use in the next 3-5 years.
The 2012 Integrated Medical, Public Health, Preparedness and Response Training Summit, May 21-25, 2012 Nashville, Tennessee
The 2012 Integrated Medical, Public Health, Preparedness and Response Training Summit will be held May 21-25 in Nashville, Tennessee. This training summit brings together HHS partners including the National Disaster Medical System (NDMS), the Medical Reserve Corps (MRC), the Emergency System for Advance Registration of Volunteer Health Professionals (ESAR-VHP), and the United States Public Health Service (USPHS). The Integrated Training Summit is co-sponsored by the Chesapeake Health Education Program, Inc (CHEP). The 2012 Integrated Medical, Public Health, Preparedness and Response Training Summit is sponsored by the U.S. Department of Health and Human Services (HHS).
Business Strategies for Biologics: Positioning and Partnering for the Biopharmaceutical Evolution, October 5-6 2011, Boston, Massachusetts
Business Strategies for Biologics: Positioning and Partnering for the Biopharmaceutical Evolution will be held hosted October 5-6th, 2011 in Boston, Massachusetts. The two day conference will cover on-trend topics regarding the future of pharma, sourcing strategies for biologics, regulatory challenges, and opportunities in biosimilars. Speakers will include senior personnel from Merck, Novartis, Pfizer, Sanofi, Genentech/Roche, and Boehringer Ingelheim.
Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, today announced that it has raised $15 million in an initial round of financing through a private placement with a syndicate of venture and qualified investors. Riverbank Capital Securities Inc., a FINRA member broker dealer, acted as placement agent in connection with the financing.
Active immunotherapy is an emerging therapeutic modality for the treatment of multiple cancer indications. Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of cutting-edge immunotherapeutic products to treat different cancer indications. Kite’s lead products include antigens associated with a wide variety of tumor types, and are initially being developed for the treatment of renal cell carcinoma and hepatocellular carcinoma. These potential therapies are designed to stimulate a patient’s own immune system to help fight cancer and could represent novel strategies for the management and treatment of these otherwise incurable diseases. Kite is based in Los Angeles, CA.
HHS releases new strategic plan to advance vaccine and immunization science and policy for the next decade
The U.S. Department of Health and Human Services today unveiled a new National Vaccine Plan to enhance coordination of all aspects of federal vaccine and immunization activities. Its goal is to ensure that all Americans can access the preventive benefits of vaccines.
The plan is a wide-ranging guide to innovating the nation’s vaccine system. It addresses such issues as research and development, supply, financing, distribution, safety, global cooperation, and informed decision-making among consumers and health care providers.
This is the first update of the National Vaccine Plan since the original version in 1994.
“Vaccines are a critical cornerstone of the public health system,” said Assistant Secretary for Health Howard K. Koh, M.D., M.P.H. “The National Vaccine Plan articulates a vision that will ensure that the nation’s prevention strategies protect the public for the next decade and beyond.”
Despite the success of vaccines in reducing death and disability over the last century, many Americans still suffer from infectious diseases that can be prevented by vaccines. The plan offers innovative approaches to improve delivery of existing vaccines and to spur development of new products to prevent infectious disease.
The National Vaccine Plan is the product of an extensive stakeholder feedback process. It integrates input from public health and medical experts, a wide range of federal, state and local government officials, and perhaps most importantly, the public.
“This plan is a 10-year vision for the nation to more effectively prevent infectious diseases and reduce adverse reactions to vaccines,” said Director of the National Vaccine Program Office and Deputy Assistant Secretary for Health Bruce Gellin, M.D., M.P.H. “The plan is national in scope. Implementation will require a well-organized effort among stakeholders, including federal, state and local policymakers, health care providers, manufacturers, academia, philanthropic organizations, and the public.”
Next steps include a series of regional meetings with stakeholders in the spring and summer of 2011, which will focus on how to implement the strategies laid out in the National Vaccine Plan. The final implementation plan will be completed by the end of 2011.